Aspire Biopharma Holdings, Inc. reported that on April 15, 2026, it closed the second tranche of a securities offering, raising approximately $10 million from 12,500 shares of Series A Convertible Preferred Stock. This follows the first tranche completed on February 6, 2026, which generated $11 million, totaling $21 million for the acquisition of Dura Driver Control Systems and other corporate needs.